Q2 EPS Estimates for Legend Biotech Reduced by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Equities researchers at HC Wainwright lowered their Q2 2026 earnings estimates for Legend Biotech in a report issued on Monday, March 16th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of $0.06 for the quarter, down from their prior forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s Q3 2026 earnings at $0.14 EPS, Q4 2026 earnings at $0.26 EPS and FY2027 earnings at $2.28 EPS.

Legend Biotech (NASDAQ:LEGN) last released its earnings results on Tuesday, March 10th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.18. The firm had revenue of $306.30 million during the quarter, compared to the consensus estimate of $310.21 million. Legend Biotech had a negative return on equity of 21.93% and a negative net margin of 28.86%.The firm’s revenue for the quarter was up 64.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.07 earnings per share.

Several other research analysts have also recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Legend Biotech in a research note on Monday, December 29th. Truist Financial set a $70.00 price target on shares of Legend Biotech in a research report on Tuesday, March 10th. Rothschild & Co Redburn downgraded shares of Legend Biotech from a “buy” rating to a “neutral” rating and set a $24.00 price target for the company. in a report on Thursday, February 12th. Barclays reduced their price objective on shares of Legend Biotech from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Wednesday, February 4th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $69.00 price objective on shares of Legend Biotech in a research note on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $58.31.

Legend Biotech Stock Performance

Shares of LEGN stock opened at $18.21 on Wednesday. Legend Biotech has a 1 year low of $16.24 and a 1 year high of $45.30. The business’s fifty day moving average is $19.20 and its 200-day moving average is $25.87. The stock has a market cap of $3.37 billion, a PE ratio of -22.76 and a beta of 0.07.

Institutional Investors Weigh In On Legend Biotech

Hedge funds have recently modified their holdings of the stock. Clearstead Advisors LLC boosted its position in shares of Legend Biotech by 76.5% in the 3rd quarter. Clearstead Advisors LLC now owns 847 shares of the company’s stock valued at $28,000 after purchasing an additional 367 shares during the period. Parallel Advisors LLC raised its holdings in Legend Biotech by 171.9% during the 3rd quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock worth $34,000 after buying an additional 662 shares during the period. OFI Invest Asset Management raised its holdings in Legend Biotech by 102.6% during the 3rd quarter. OFI Invest Asset Management now owns 1,228 shares of the company’s stock worth $40,000 after buying an additional 622 shares during the period. Raymond James Financial Inc. purchased a new stake in Legend Biotech during the second quarter valued at about $78,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Legend Biotech during the third quarter valued at about $104,000. 70.89% of the stock is owned by hedge funds and other institutional investors.

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.